[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-142836-105":59,"doc-detail-142836-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","iprazochrome","Iprazochrome","","Iprazochrome is a serotonin antagonist used for migraine prophylaxis and for managing diabetic retinopathy. It is administered in usual oral doses of 2.5 to 5 mg three times daily. The entry provides multiple recorded names and detailed chemical and regulatory identifiers including molecular composition, CAS number, and ATC classifications. It also includes a structural description and related reference context for comparison within migraine triptan therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/iprazochrome/142836/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/iprazochrome/142836.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-06","2026-08-25",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is iprazochrome used for?","Question",{"text":112,"@type":113},"Iprazochrome is used for migraine prophylaxis and for the management of diabetic retinopathy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is iprazochrome typically dosed?",{"text":117,"@type":113},"Usual oral doses are 2.5 to 5 mg three times daily.",{"name":119,"@type":110,"acceptedAnswer":120},"What key identification information is provided for iprazochrome?",{"text":121,"@type":113},"The entry lists alternative names and gives molecular composition, CAS number (7248-21-7), and ATC classifications (N02CX03 and veterinary N02CX03).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},142836,1787689641,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":81},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Feverfew/Naratriptan Hydrochloride 623  \nMigraine. For comparison of the relative benefits of different triptans in migraine, see under Sumatriptan, p.627.  \nFurther references.  \n1. Rapoport A, et al. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002; 42 (suppl 2): S74–S83 .  \n2. Ryan R, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002; 42 (suppl 2): S84–S92 .  \n3. Poolsup N, et al. Efficacy and tolerability offrovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther 2005; 30: 521–32.  \nPreparations  \nProprietary Preparations (details are given in Part 3) Austria: Eumitan; Cz.: Fromen; Recur; Fin.: Migard; Fr.: Tigreat; Ger.: Allegro; Gr.: Migard; Migralin; Irl.: Frovex; Ital.: Auradol; Rilamig; Neth.: Fromirex; Migard; Port.: Dorlise; Migard; Spain: Forvey; Perlic; Switz.: Menamig; UK: Migard; USA: Frova.  \nIprazochrome (rINN)  \nIpratsokromi; Iprazochromum; Iprazocromo; Iprazokrom. 3-Hydroxy-1-isopropyl-5,6-indolinedione 5-semicarbazone.  \nИпразохром  \nC 12 H 16N4O3 = 264.3.  \nCAS — 7248-21-7.  \nATC—N02CX03 .  \nATC Vet — QN02CX03 .  \nH2N  \nO  \nC  \nN H  \n N  \nO  \nOH  \nN  \nCH(CH 3)2  \nProfile  \nIprazochrome is a serotonin antagonist used in the prophylaxis of migraine (p.616) and in the management of diabetic retinopathy. It has been given in usual oral doses of 2.5 to 5 mg three times daily.  \nPreparations  \nProprietary Preparations (details are given in Part 3)  \nGer.: Divascan†; Hung.: Divascan; Pol.: Divascan.  \nMethysergide (BAN, USAN, rINN)  \n1-Methyl-D-lysergic Acid Butanolamide; Méthysergide; Methysergidum; Metisergida; Metysergid; Metysergidi. N-[1-(Hydroxymethyl)propyl]-1-methyl-D-lysergamide; 9,10-DidehydroN-[1-(hydroxymethyl)propyl]-1,6-dimethylergoline-8β-carboxamide.  \nМетизергид  \nC21 H27N3O2 = 353.5.  \nCAS — 361-37-5.  \nATC—N02CA04 .  \nATC Vet — QN02CA04 .  \nCH3  \nOH  \nCH3  \nMethysergide Maleate (BANM, rINNM)  \nMaleato de metisergida; Méthysergide, Maléate de; Methysergidi Maleas.  \nМетизергида Малеат  \nC21 H27N3O2, C4 H4O4 = 469.5.  \nCAS — 129-49-7.  \nATC—N02CA04 .  \nATC Vet — QN02CA04 .  \nPharmacopoeias. In Br. and US.  \nBP 2008 (Methysergide Maleate). A white or almost white crystalline powder which may have a yellow or pink tinge; odourlessor almost odourless. Slightly soluble in water and in methyl alcohol; practically insoluble in chloroform and in ether. A 0.2% solution in water has a pH of 3.7 to 4.7. Store at a temperature of 2° to 8°. Protect from light.  \nUSP 31 (Methysergide Maleate). A white to yellowish-white or reddish-white, crystalline powder. Is odourless or has not more than a slight odour. Soluble 1 in 200 of water and 1 in 165 of alcohol; soluble 1 in 3400 of chloroform; practically insoluble in ether. pH of a 1 in 500 solution is between 3.7 and 4.7. Store in airtight containers at a temperature of 2° to 8°. Protect from light.  \nAdverse Effects  \nGastrointestinal effects such as nausea, vomiting, heartburn, and abdominal pain are common on initial treatment with methysergide maleate, as are dizziness and drowsiness. Other CNS effects reported include ataxia, insomnia, weakness, restlessness, lightheadedness, euphoria, and hallucinations. Peripheral or localised oedema, leg cramps, and weight gain have occurred and there have been occasional reports of skin rashes, loss of hair, joint and muscle pain, neutropenia, and eosinophilia. Orthostatic hypotension and tachycardia have been observed. There have been isolated reports of myocardial infarction particularly in patients with ischaemic heart disease or when given with other vasoconstrictive drugs, both of which are contra-indications formethysergide therapy.  \nArterial spasm has occurred in some patients, and may present as paraesthesia of the extremities or anginal pain, as with ergotamine (p.620); if such symptoms occur methysergide should be withdrawn, although rebound headaches may be experienced if it i","cbCaikEOPGoExqFe","https://ap.wps.com/l/cbCaikEOPGoExqFe","pdf",86173,"English","# Iprazochrome\n## Profile\n## Identifiers and classifications\n## Preparations (proprietary names)","[{\"question\":\"What is iprazochrome used for?\",\"answer\":\"Iprazochrome is used for migraine prophylaxis and for the management of diabetic retinopathy.\"},{\"question\":\"How is iprazochrome typically dosed?\",\"answer\":\"Usual oral doses are 2.5 to 5 mg three times daily.\"},{\"question\":\"What key identification information is provided for iprazochrome?\",\"answer\":\"The entry lists alternative names and gives molecular composition, CAS number (7248-21-7), and ATC classifications (N02CX03 and veterinary N02CX03).\"}]","Iprazochrome | PDF"]